We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genes behind Gestation Length and Preterm Delivery Identified

By LabMedica International staff writers
Posted on 21 Sep 2017
Despite evidence that genetic factors contribute to the duration of gestation and the risk of preterm birth, robust associations with genetic variants have not been identified. More...
Preterm birth and gestational duration in general, is a complicated phenotype that is affected by both maternal and fetal genomes.

The definition of preterm birth as a dichotomous trait on the basis of a somewhat arbitrary cutoff of 37 weeks of gestation, rather than time of birth for a specified level of fetal maturity or as a continuous trait limits the interpretation of data and reduces the statistical power to detect association.

An international team of scientists working with those at the University of Gothenburg (Sweden) based a study on genetic data and information on gestation length for 43,568 women of mainly European origin. The information was made available to the team by 23andMe (Mountain View, CA, USA), one of the world's largest players in DNA testing for personal use. The company's tests are based on submitted saliva samples. Female participants who had given birth also had to state how long their pregnancies had been.

The reference group consists of 8,643 women in Denmark, Finland and Norway. The information on them comes from traditional health registers. A crucial factor in this study was the combination of a very large group, and a register-based group for which the results could be replicated. The genome-wide association studies showed that there are four genes with a clear link to gestation length: Early B-Cell Factor 1 (EBF1), Eukaryotic Elongation Factor, Selenocysteine-TRNA Specific (EEFSEC), Angiotensin II Receptor Type 2 (AGTR2) and Wnt Family Member 4 (WNT4). Commonly occurring variants of the first three genes also appeared to have a determining influence on the likelihood of preterm birth that is delivery before 37 full weeks. Variants of a further two genes could also be associated with gestation length, which was most evident in the reference group.

Bo Jacobsson, MD, PhD, a professor of Obstetrics and a senior co-author of the study said, “Our findings open up a window on better understanding of how human gestation length is governed and why labor might start too soon. It's less about predicting who will end up in one situation or the other; now we need to move to the lab bench and conduct some studies into how this works together with various environmental factors.” The study was published on September 6, 2017, in The New England Journal of Medicine.

Related Links:
University of Gothenburg
23andMe

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.